- AdventHealth
AdventHealth for Women Altamonte, Celebration and Winter Park Campuses Named Level II Maternal Care Verified Facilities
AdventHealth for Women Orlando recently became the first facility in Florida to earn a Level IV Maternal Center Designation through The Joint Commission’s Maternal Levels of Care (MLC) Verification program. The highest level awarded, this designation recognizes the ability to provide on-site medical and surgical care of the most complex maternal conditions and critically ill pregnant women and fetuses throughout antepartum, intrapartum and postpartum care. AdventHealth for Women’s Altamonte, Celebration and Winter Park hospitals were verified as Level II facilities, recognizing their ability to care for moderate to high-risk perinatal conditions.
Offered in collaboration with the American College of Obstetricians and Gynecologists (ACOG), the MLC Verification program was designed to improve maternal patient outcomes. All four AdventHealth facilities underwent a comprehensive on-site review to verify the level of care provided.
Executive Medical Director at AdventHealth for Women
“This is a significant achievement that validates the levels of maternity care we provide to the women we serve,” shares Rizwana Fareeduddin, MD, Executive Medical Director, AdventHealth for Women. “The Joint Commission reviewed our policies, standard operating procedures, multidisciplinary collaboration and workflows, clinical availability, and resources to verify that AdventHealth for Women Orlando provides the highest level of obstetrics care available.”
The MLC Verification program was developed using ACOG’s Levels of Maternal Care Obstetric Care Consensus (OCC) clinical guidance, which includes comprehensive uniform definitions, a standardized description of maternity facility capabilities and personnel, and a framework for integrated systems that address maternal health needs.
“The Joint Commission commends AdventHealth for Women Orlando for being named a Level IV maternal care verified facility and for its efforts to standardize maternal care and reduce maternal morbidity and mortality,” says Mark Pelletier, RN, MD, chief operating officer, Accreditation and Certification Operations, and chief nursing executive, The Joint Commission. “The Maternal Levels of Care Verification program will help AdventHealth for Women strengthen regionalized care for mothers and babies in its community.”
AdventHealth for Women remains committed to improving maternal health outcomes and is currently focused on reducing the c-section rate among low-risk, first-term mothers (nulliparous, term, singleton, vertex/NTSV). C-section delivery increases the risk of uterine rupture and placenta accreta in future pregnancies as well as infection, blood clots, hemorrhage, hysterectomy and maternal death. As part of its work with the Florida Perinatal Quality Collaborative’s Postpartum Access & Continuity of Care (PACC) initiative, AdventHealth for Women is also working to reduce readmissions and improve postpartum care. Specific efforts include improving education to women about self-care, post-birth warning signs, risk factors and birth spacing as well as scheduling patients for two-week follow-up visits instead of waiting the traditional six to eight weeks after birth. Additional initiatives are focused on improving care for at-risk populations and addressing social determinants of health.
If you’d like to learn more about these initiatives, contact us here.
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...
AdventHealth Research Institute and NESTRE Health & Performance Announce Collaboration to Advance Neurocognitive Health and Performance Through Cognitive Training
With an aging population and increases in the prevalence of neurological conditions like Alzheimer’s disease and dementia, physicians and patients alike continue to seek new tools and approaches to...
Empowering emerging women leaders
ATHENA NextGen’s Karen Keene joins AdventHealth’s Karen Corbin in a discussion about empowering the next wave of women leaders.